Continous Blood Glucose Monitoring Global Market Report 2024

A continuous blood glucose monitoring device plays a crucial role in helping individuals better regulate glucose levels throughout the day, leading to fewer instances of low blood glucose situations.

The main components in continuous blood glucose monitoring devices include insulin pumps, sensors, transmitters, and receivers. Insulin pumps are compact, computerized devices that are programmed to administer pre-determined doses of insulin at specific intervals. These devices are particularly utilized by individuals with type 1 diabetes, type 2 diabetes, gestational diabetes, and critical care patients. The end-users for continuous blood glucose monitoring devices include hospitals, homecare diagnostics, and various other settings.

The continuous blood glucose monitoring market research report is one of a series of new reports that provides continuous blood glucose monitoring market statistics, including continuous blood glucose monitoring industry global market size, regional shares, competitors with a continuous blood glucose monitoring market share, detailed continuous blood glucose monitoring market segments, market trends and opportunities, and any further data you may need to thrive in the continuous blood glucose monitoring industry. This continuous blood glucose monitoring market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The continous blood glucose monitoring market size has grown rapidly in recent years. It will grow from $8.09 billion in 2023 to $9.68 billion in 2024 at a compound annual growth rate (CAGR) of 19.7%. The growth observed in the historical period in the continuous blood glucose monitoring device market can be attributed to several factors, including the increase in diabetes prevalence, growing regulatory compliance, the demand for remote monitoring solutions, expansion into emerging markets, and a rise in healthcare spending. These factors collectively contributed to the expansion and adoption of continuous blood glucose monitoring devices during that time, reflecting the increasing need for effective solutions in managing diabetes and related conditions.

The continous blood glucose monitoring market size is expected to see exponential growth in the next few years. It will grow to $20.44 billion in 2028 at a compound annual growth rate (CAGR) of 20.5%. The anticipated growth in the forecast period in the continuous blood glucose monitoring device market can be attributed to various factors, including the growing aging population, the expansion of home healthcare services, the rise in telehealth services, increased healthcare expenditure, and a general rise in disposable income. Major trends expected during this period include the integration of wearable technologies, the incorporation of artificial intelligence and machine learning, advancements in sensor technology for enhanced accuracy, and increased partnerships and collaborations within the healthcare industry. These trends collectively indicate a dynamic and evolving landscape in continuous blood glucose monitoring, reflecting advancements in technology and collaborative efforts to improve healthcare outcomes.

The continuous blood glucose monitoring market is anticipated to experience growth, propelled by the increasing prevalence of diabetes. Diabetes, a health condition characterized by fluctuating blood glucose levels, can benefit significantly from the use of blood glucose monitoring devices. These devices aid in detecting trends and patterns, offering a comprehensive view of a diabetic individual's condition. The International Diabetes Federation (IDF) reported in its IDF Diabetes Atlas 10th edition in July 2021 that the estimated global population of individuals living with diabetes is projected to reach 643 million by 2030 and further increase to 783 million by 2045. This rise, from approximately 537 million adults in 2021, highlights the escalating prevalence of diabetes as a driving force behind the continuous blood glucose monitoring market's growth.

The proliferation of hospitals is poised to contribute to the expansion of the continuous blood glucose monitoring market. Hospitals, dedicated to providing medical or surgical treatment, find continuous blood glucose monitoring crucial for precise and ongoing monitoring of blood glucose levels, particularly for patients with diabetes or those at risk of glucose-related complications. According to Discovery Therapy in September 2023, the US had around 6,090 hospitals in 2021, while globally, there were approximately 165,000 hospitals. Additionally, the American Hospital Association reported in May 2023 that there were 6,129 hospitals in America in 2022. The increased number of hospitals globally is expected to drive the growth of the continuous blood glucose monitoring market.

Technological advancements emerge as a significant trend shaping the continuous blood glucose monitoring market. Key players in the market are actively engaged in developing advanced technological solutions to enhance their market presence. In 2021, Philips, a Netherlands-based health technology company specializing in glucose monitoring devices, launched non-invasive monitors for COPD patients based on ExpiraFlow technology. These non-invasive monitors enable healthcare professionals to detect and screen expiratory flow limitations, offering a valuable tool for optimal home care therapy. This focus on technological innovation underscores the commitment of major companies to staying at the forefront of the continuous blood glucose monitoring market.

Prominent companies in the diabetes care devices market are actively pursuing innovation with the introduction of new products, exemplified by the Medtronic Extended infusion set, aimed at enhancing their profitability. The Medtronic Extended infusion set is a tubing system designed to deliver insulin from the pump to the body and boasts a wear duration of up to 7 days. Medtronic Plc., a US-based medical equipment manufacturer, launched this product in select European countries in April 2021. Initially available for purchase in specific European nations, including Finland and Belgium, the product is set for a gradual rollout to additional European countries. The Medtronic Extended infusion set includes an all-in-one serter, streamlining the process of changing the set and making it fast and straightforward. Notably, its innovative technology and alternative materials allow for double the wear duration compared to other Medtronic infusion sets, typically approved for 2-3 days of use.

In a strategic move in May 2023, Medtronic PLC., an Ireland-based medical device company, acquired EOFlow for an undisclosed amount. This acquisition is geared towards strengthening Medtronic's diabetes product portfolio and expanding its capacity to offer comprehensive support to a larger global community managing diabetes, all within a unified Medtronic ecosystem. EOFlow Co. Ltd., based in South Korea, is recognized for manufacturing the insulin patch pump EOPatch. This strategic acquisition aligns with Medtronic's commitment to continuous growth and innovation in the diabetes care devices market.

Major companies operating in the continous blood glucose monitoring market include F. Hoffmann-La Roche Ltd., Lifescan Inc., Medtronic plc., Abbott Laboratories, GlySens Inc., Arkray, Senseonics Holdings Inc., Glysure Limited, Nemaura Medical Inc., Tandem Diabetes Care Inc., Goldsite Diagnostics Inc., AgaMatrix Inc., B. Braun Melsungen AG, Ypsomed Holding AG, Terumo Corporation, Orsense Ltd., Dexcom Inc., A. Menarini Diagnostics, Echo Therapeutics Inc., Johnson & Johnson Services Inc., Ascensia Diabetes Care Holdings AG, Insulet Corporation, Medtrum Technologies Inc., Texas Instruments Inc., Beta Bionics Inc., Bigfoot Biomedical Inc., One Drop Inc., DarioHealth Corp., MedAngel BV, GluSense Ltd., PKvitality, Nemotecnia S.A.

North America was the largest region in the continuous blood glucose monitoring market in 2023. The regions covered in the continuous blood glucose monitoring market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the continuous blood glucose monitoring market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The continuous blood glucose monitoring market consists of sales of real-time continuous glucose monitoring, and intermittently scanned continuous glucose monitoring. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.